4.4 C
New York
Monday, January 25, 2021
Home Health No One Raises Questions on Indian Biotech Covaxin

No One Raises Questions on Indian Biotech Covaxin

Krishna Ella, MD, Bharat Biotech, took aim at critics, saying the approval has been based on the conditions set by CDSCO (2019). We’re not a company that doesn’t have the experience of making vaccines. We have great experience in making vaccines.

Politics is in full swing after two vaccines were approved in India. Meanwhile, Bharat Biotech MD Krishna Ella has made a big statement. He said that the vaccine is being politicized by some people, I want to state clearly that no member of my family is associated with any political party. So, it should not be politicized.

We are not just doing clinical trials in India, “said MD Krishna Ella. We are also conducting clinical trials in Pakistan, Nepal, Bangladesh, and other countries. India Biotech’s Cowaxin has been approved by the Drugs Controller General of India (DCGI) for emergency use. The opposition has alleged that the sanction has been granted in haste.

Have a good experience of making vaccines

Krishna Ella took aim at critics, saying the approval has been given based on the conditions laid down by the Central Drugs Standard Control Organisation (CDSCO) 2019. We’re not a company that doesn’t have the experience of making vaccines. We have great experience in making vaccines. We are working for 123 countries. We are the only company to have such an experience. So don’t question our vaccine.

Such people should exercise restraint and read articles that are published on data on the Internet. So far, more than 70 articles have been published in international journals.

The US doesn’t even have this facility

The US also doesn’t have this feature. We are there to help the public health emergency in the world, no matter what part it is. On the third phase trial, he said that it will expire in the next two-three days and the data will be available by February or March.

He said Merck’s Ebola vaccine never completed the Human clinical trial, but the WHO had allowed emergency experiments for Liberia and Guinea. Krishna Ella said that we now have 200 million doses. We are aiming to achieve 70 million dose capacity at four centers. Three of them are in Hyderabad and one in Bengaluru. Initially, the price of the vaccine may be slightly higher.

Shashi Tharoor had raised the question

In the past, Congress leader Shashi Tharoor had said that the phase three trial of Bharat Biotech’s covaxin is yet to take off, so why was it given a mission before that? Shashi Tharoor was also questioned by former minister Jairam Ramesh. On this, the Centre health minister had said that vaccine has been allowed only after all necessary investigations and all standards have been met which are valid in the world.

Tharoor then responded again and tweeted that you say it will not have repercussions, soothing. But you’re saying ‘it’s likely to work’, ‘it’s as effective as the other vaccine’, it doesn’t give assurances. Congress leader Shashi Tharoor further wrote that the possibility can be decided only if there is a clinical trial of phase-3.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments